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Science in the Administrative Process
I. INTRODUCTION
At the end of the sixties, Kenneth Davis wrote a seminal book' on the
problem of securing justice in a legal system that leaves administrators
uncontrolled scope for the exercise of discretion. In examining possible
techniques for confining and structuring discretion, Davis concluded that:
Administrative rule-making is the key to a large portion of all that needs to be
done. To whatever extent is practical and consistent with the need for indi-
vidualized justice, the discretion of officers in handling individual cases should be
guided by administrative rules adopted through procedure like that prescribed by
the Administrative Procedure Act. Agencies through rule-making can often move
from vague or absent statutory standards, and then, as experience and under-
standing develop, to guiding principles, and finally, when the subject matter
permits, to precise and detailed rules. The constant objective, when discretionary
power is excessive, should be for earlier and more elaborate administrative rules.2
Davis regarded open rule-making as an indispensable technique for control-
ling administrative behavior, for he saw in openness "a natural enemy of
arbitrariness, a natural ally in the fight against injustice."3
Since these views were articulated, a succession of laws aimed at pro-
tecting public health, safety and the environment have conferred new discre-
tionary duties on administrative agencies in the United States. Federal
regulators are required to predict the future impact of new industrial products
and processes and to devise measures for mitigating projected risks. Statu-
tory grants of authority are couched in broad and imprecise terms. Laws
such as the Occupational Safety and Health Act4 or the Toxic Substances
Control Act5 instruct administrators to determine "unreasonable risk" or to
establish "feasible" safety standards, taking into account the costs and
benefits of alternative courses of action.
Inevitably, administrative implementation of these laws moves forward
in an atmosphere of uncertainty.6 The hazards of modem technology,
particularly those related to toxic substances in the environment, often
become apparent only after decades of development. Federal health and
safety legislation recognizes as a matter of policy that regulators should
not wait for harm to materialize before undertaking appropriate remedial
action. Accordingly, government agencies must assess the probability of future
harm and abate significant risks to health and the environment even when
scientific support for their action remains controversial or incomplete. Yet
the prospect of regulatory intervention unconstrained either by firm legis-
1 Davis, Discretionary Justice (Baton Rouge: Louisiana State University Press,
1969).
2 Id. at 219.
3 Id. at 226.
4 Pub. L. No. 91-596, 29 U.S.C. §§ 651-678 (1970).
5 Pub. L. No. 94-469, 15 U.S.C. §§ 2601-2629 (1976).
6 Although this paper addresses only the problems associated with scientific un-
certainty, administrative agencies have to deal with uncertainty in many other forms as
well, for example, in their assessment of the costs and benefits of proposed regulatory
action.
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lative standards or by definite scientific principles promotes new concern
about arbitrary and excessive administrative action.
Given the inescapable need for administrators to contend with un-
certainty in health and safety regulation, does Davis' formula for channelling
and containing administrative discretion still retain its validity? In particular,
does the device of open administrative rule-making offer a sufficient
guarantee against arbitrary resolution of scientific and technical controversies?
These questions are addressed below in the context of one recent regulatory
proceeding: the ambitious attempt by the United States Occupational Safety
and Health Administration (OSHA) to establish rules for the identification,
classification and regulation of carcinogens in the workplace. In reviewing
the history and substance of OSHA's decision-making in this case, it is
argued that the agency's effort, although it amply met the standard of "early
and elaborate" rule-making, ultimately broke down on two counts. It failed
to accommodate crucial differences between administrative and scientific
criteria of legitimacy and it paid insufficient heed to the political aspects of
the scientific controversies uncovered during the rule-making process.
In the course of developing its regulations on carcinogenic substances7
-informally known as the "cancer policy"-OSHA was confronted by
conflicting expert views on a wide range of theoretical and methodological
issues. Areas of significant disagreement included the percentage of cancers
attributed to occupational exposure, the criteria used to evaluate animal tests
and epidemiological studies, and the factors considered in assigning chemicals
to different categories of risk. OSHA attempted to forge a consensus on most
of these issues by means of procedural techniques deeply familiar to Ameri-
can administrative agencies: hearings, adversarial testimony, a detailed public
record and officially published regulations. Throughout the protracted regu-
latory proceeding, OSHA seemed to assume that by adhering to the canons
of good administrative practice it would produce a workable and socially
acceptable policy. But in so doing, the agency overlooked the "mixed"
character of its regulatory task. It should have been apparent from the
outset that a rule-making process so closely tied to complex scientific con-
siderations would have to meet a dual standard of legitimacy-the scientific
as well as the procedural-and that in important ways the two would prove
difficult to reconcile. Moreover, in seeking principled solutions to the regu-
latory debate, OSHA underestimated the strength of the political cleavages
underlying what appeared to be conflicts among competing scientific theories
of carcinogenisis.
The story of the cancer policy may be told simply as one of regulatory
short-sightedness. But in the context of a broader concern with regulatory
reform, it is important to ask whether other positive lessons can be drawn
from OSHA's experience. Could the agency have used any other institutional
or procedural arrangements to fulfil its regulatory purpose more effectively?
After examining these issues the paper will conclude with an inquiry into
alternative approaches that have been followed in European countries faced
7 Identification, Classification and Regulation of Potential Occupational Carcinogens,
45 Fed. Reg. 5001-5296 (1980).
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with similar regulatory problems. On the whole, European agencies have
been less ambitious than OSHA in defining their regulatory objectives, but
more successful in achieving a scientific and political consensus on the con-
trol of occupational carcinogens. Though the experiences of regulatory
authorities are notoriously difficult to duplicate in other national settings,
it is instructive to ask whether the European examples offer any suggestions
for regulatory reform in the United States.
II. LEGISLATIVE CONTROL OF CARCINOGENS: THE DELANEY
PRINCIPLE
OSHA's concern with carcinogens was rooted in a long-standing pre-
occupation of the American regulatory policy with controlling public ex-
posure to such substances. Over the last quarter century, Congress and the
courts, as well as several administrative agencies, have devoted considerable
energy to the problem of regulating carcinogens in the human environment.
OSHA's generic cancer policy can only be understood and evaluated against
the backdrop of these earlier efforts; ironically, it appears that the federal
government's initial activities in this area achieved a measure of pragmatic
success by avoiding the path of open rule-making.
Chemical carcinogens were first identified for special regulatory treat-
ment in 1958 when Congress substantially revised the existing law for
controlling food additives. Incorporated in the 1958 amendment to the Food,
Drug, and Cosmetic Acts was a provision introduced by Representative
James Delaney of New York stipulating that no additive should be cleared
for use: "[I]f it is found to induce cancer when ingested by man or animal,
or if it is found, after tests which are appropriate for the evaluation of the
safety of food additives, to induce cancer in man or animal."9 The effect of
this provision, popularly known as the Delaney Clause,'0 is to ban from the
food supply any additive designated as carcinogenic by the Food and Drug
Administration (FDA) on the basis of animal or human evidence. The
provision has been widely interpreted as laying down a "zero risk" policy
for carcinogenic substances used in food preparation.",
The Delaney Clause incorporated a number of assumptions about
cancer causation and cancer research that won broad support from the
international scientific community in the mid-1950s. Toxicologists generally
subscribed to the view that any substance found to cause cancer in animals
should also be regarded as a potential human carcinogen. Moreover, it was
8 Food Additives Amendment of 1958, Pub. L. No. 85-929, codified in scattered
sections of the Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. (1938).
9021 U.S.C2. § 348 (c)(3) (A) (1962).
1oOriginally applicable only to food additives, the Delaney Clause was sub-
sequently added to the colour additive and animal drug provisions of the Food, Drug,
and Cosmetic Act as well. See 21 U.S.C. § 376(b) (5) (B)(1962) (colour additives) and
21 U.S.C. § 360b(d) (1) (H) (1968) (new animal drugs).
"1 See, e.g., Blank, The Delaney Clause: Technical Nalvetd and Scientific Advocacy
in the Formulation of Public Health Policies (1974), 62 Calif. L. Rev. 1084 and
Martin, The Delaney Clause and Zero Risk Tolerance (1979), 34 Food Drug Cosmetic
LJ. 43.
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commonly believed that no safe "threshold" limit could be specified for
exposure to carcinogens, since such substances were known to produce ir-
reversible effects even at very low doses. These views were summarized in
a statement issued by the International Union Against Cancer 12 at its 1956
symposium on chemical food additives: "Any substance which causes cancer
in mian or which, when tested under (specified) conditions, is shown con-
clusively to be a carcinogen at any dosage level, for any species of animal,
following administration by any route, should not be considered innocuous
for human consumption." 3 In his remarks to the House on August 25, 1958,
Delaney introduced this statement into the legislative record as scientific
support for his proposed amendment. 14
From the standpoint of later policy, however, it is equally important
to stress what was not known or generally agreed upon in 1958. Since no
national or international research institution had at that time undertaken
systematic testing of chemicals for carcinogenicity, 15 there were no accurate
estimates of the number of potentially carcinogenic chemicals actually present
in the human environment. Thus, policy-makers could reasonably conclude
that it would be economically feasible to exclude all such substances from
food. The techniques of analytical chemistry were not yet sufficiently deve-
loped to permit the detection of chemical substances in food at the parts per
billion or parts per trillion level. Available technology supported the view
that relatively few carcinogens would ever be subject to regulation under the
Delaney Clause. Finally, the mechanisms by which chemicals produce can-
cerous changes in human and animal tissue were very poorly understood and
there was no widespread consensus as to the proper methodology for design-
ing and carrying out long term feeding experiments on test animals.
The formulation of the Delaney Clause implicitly took notice of these
scientific unknowns. In contrast to its rigidity on the issue of threshold doses,
the provision granted FDA considerable discretion to interpret and, if
necessary, ignore experimental evidence of carcinogenicity. Recognizing that
experts might differ in evaluating the results of animal bio-assays, the
12 IUAC is an international non-governmental scientific organization which has
consultative status with the World Health Organization. Established in 1935, IUAC
became interested in potentially carcinogenic food additives as early as 1939. In 1956,
IUAC sponsored a symposium on cancer hazards from chemical additives which pro-
vided some of the scientific impetus for the adoption of the Delaney Clause in the U.S.
Is See Proceedings of Symposium on Potential Cancer Hazards from Chemical
Additives and Contaminants in Foodstuffs (1957), 13 Acta Union International contre
le Cancer 179-363.
14 Extension of remarks by Representative James J. Delaney of New York on the
House passage of H.R. 13254 (Cong. Rec. of August 25, 1958, 85th Cong., 2d Sess.),
reprinted in Dunn, Legislative Record of the 1958 Food Additives Amendment to the
Federal Food, Drug, and Cosmetic Act (New York: Commerce Clearing House, 1958)
83-85.
15 Although the U.S. National Cancer Institute (NCI) was created in 1937, its
carcinogenicity testing programme was not systematized or coordinated with federal
regulatory priorities until the mid-seventies. NCI's testing activities underwent signi-
ficant revision and consolidation following an investigation by the General Accounting
Office in 1976 and again with the establishment of the National Toxicology Program
in 1978.
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anti-cancer provision gave FDA great latitude to determine whether such
tests were "appropriate" and whether a tested substance in fact "induced"
cancer.', These escape valves served the agency well in subsequent years.
On the whole, FDA has proved remarkably adept at avoiding strict but
politically unacceptable applications of the Delaney principle.' 7 Only in the
case of saccharin was it necessary for Congress to overrule FDA by statute's
in order to prevent an unwelcome result under the anti-cancer clause.
There is little doubt that FDA's pragmatism in implementing the
Delaney provisions of the Food, Drug, and Cosmetic Act has helped preserve
the agency's credibility in the eyes of the American public. Removing all
suspected carcinogens from the food supply no longer seems a reasonable
regulatory goal, particularly since modem analytical methods reveal trace
amounts of more and more potential carcinogens whose presence in food
was previously unsuspected. Some of these additives, such as nitrite, may
offer benefits that outweigh their carcinogenic risk. Given these realities,
FDA is clearly on politically firmer ground by refusing to ban sodium nitrite
in preserved fish, acrylonitrile in beverage containers or lead acetate in hair
dyes, than by insisting on rigid controls based on a literal reading of the
Delaney Clause.'9
FDA's flexible, pragmatic approach in applying a fairly unbending
statute entails obvious costs in terms of administrative regularity and pre-
dictability. The agency has succeeded in dealing with carcinogens as well
as it has by not structuring and confining the discretion it enjoys under the
Delaney Clause. In particular, FDA has never issued any rule or policy
statement setting forth the criteria by which it evaluates the appropriateness
of animal tests. Instead, the agency has resorted to ad hoc procedures and
arguments in interpreting scientific evidence so as to reach results consistent
with a politically acceptable regulatory outcome. 20 In the case of nitrite, for
example, the agency submitted the results of a controversial study of the
chemical's effects to an independent body of toxicological consultants. This
group concluded that the tests carried out at the Massachusetts Institute of
Technology showed no statistically significant increases in malignancies in
the test animals; accordingly, the study triggered no regulatory action under
the Delaney Clause.'
III. LITIGATION AND THE EARLY SEARCH FOR CANCER
PRINCIPLES
Although the Delaney Clause first focused federal regulatory interest
on carcinogens, it was only with the creation of the Environmental Protec-
'6See, e.g., Comment, Implementing the Anticancer Clauses of the Food, Drug.
and Cosmetic Act (1977), 44 U. Chi. L. Rev. 817 at 824-37.
17 Id. at 825-27. See also Hutt, Public Policy Issues in Regulating Carcinogens in
Food (1978), 33 Food Drug Cosmetic L. J. 541 at 544,550.
18 Saccharin Study and Labeling Act of 1977, Pub. L. No. 95-203.
10 See, e.g., Editorial, "A Carcinogen Passes", The New York Times, Nov. 9,
1980 at 18E, col. 1.
20 See authorities cited at note 17, supra.
21 Smith, Nitrates: FDA Beats a Surprising Retreat (1980), 209 Science 1100.
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tion Agency (EPA) and its earliest efforts to control environmental pollution
that the search for a principled "cancer policy" began in earnest. The effort,
first by EPA and then by OSHA, to develop firm principles for identifying
and regulating carcinogens owes much of its impetus to the involvement of
the federal courts in health and safety policy-making. Judicial activism in
this field was largely a product of the 1970s. In the first ten or fifteen years
following the enactment of the Delaney Clause FDA's activities under that
provision generated little legal controversy. In contrast, EPA became a
favoured target of environmental activists who repeatedly brought the agency
to court for its alleged failure to take firm action against a variety of chemi-
cal pollutants.
A. The Results of Judicial Intervention
Frequent litigation over the regulation of suspected carcinogens (es-
pecially pesticides) in the early 1970s produced several important side-
effects. To begin with, the courts firmly endorsed the view, seemingly shared
by Congress and large segments of the public, that chemical carcinogens
deserved special attention from federal regulatory agencies charged with
protecting public health. The Delaney Clause played a critical role in shaping
this judicial attitude. In one early case arising from EPA's failure to issue
cancellation notices for DDT, the court noted that the anti-cancer amend-
ment, although not directly applicable to pesticides:
does... indicate the magnitude of Congressional concern about the hazards
created by carcinogenic chemicals, and places a heavy burden on any adminis-
trative officer to explain the basis for his decision to permit the continued use
of a chemical known to produce cancer in experimental animals. 22
The courts also emphasized that administrative decisions to regulate car-
cinogens would be regarded, to a significant degree, as policy judgments
and, as such, would be entitled to great judicial deference.2 3
Litigation also had the effect of bringing out into the open many of the
scientific and policy issues involved in regulating carcinogens. In several
instances, the positions adopted by EPA and other agencies received explicit
judicial approval. For example, in sustaining EPA's suspension of the pesti-
cides aldrin and dieldrin, the Court of Appeals for the District of Colum-
bia Circuit approved the agency's view "that the concept of a threshold
exposure level has no practical significance where carcinogens are con-
cerned." 24 The court also condoned regulation based upon extrapolation
from animal evidence to humans:
The long latency period of carcinogens ... hinders epidemiological research, and
the ethical problems of conducting cancer experiments on human beings are too
2EDF v. Ruckelshaus 439 F.2d 584 at 596n. 41 (D.C. Cir. 1971).
23 Hercules, Inc. v. EPA, 598 F.2d 91 at 106 (D.C. Cir. 1978); EDF v. EPA,
548 F.2d. 998 at 1004n. 12 and accompanying text. (D.C. Cir. 1976) (chlordane,
heptachlor); EDF v. EPA, 489 F.2d 1247 at 1252 (D.C. Cir. 1973) (DDT). On the
other hand, the courts have exacted a high level of justification for decisions permitting
the continued use of a potential carcinogen. See EDF v. Ruckelshaus, supra note 22;
EDF v. EPA, 465 F.2d 528 at 529. (D.C. Cir. 1972).
24 EDF v. EPA, 510 F.2d 1292 at 1298 (D.C. Cir. 1975).
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obvious to require discussion. Although extrapolation of data from mice to men
may be quantitatively imprecise, it is sufficient to establish a "substantial likeli-
hood" that harm will result.25
While litigation spurred EPA to more intensive efforts in regulating carcino-
gens, on the whole it also strengthened the agency's credibility. Not only
were EPA's specific scientific determinations approved by the courts but,
taken together, the pesticide cases reinforced the principle of judicial
deference to administrative agencies in areas of technically complex decision-
making.
B. The EPA Cancer Principles
A passage of the Federal Environmental Pesticide Control Act of 197226
assigned to EPA a regulatory task of almost impossible magnitude: to register
all new pesticides and to re-register the 35,000 or so pesticides already in use
in the United States.27 The law also provided for cancellation of a pesticide
registration if the substance was found to cause "unreasonable adverse effects
on the environment."28 Strict timetables were laid down for regulatory action.
For example, only ninety days were provided for a final decision in a pesti-
cide cancellation proceeding.29 EPA's internal rules further divided this
period between the Administrative Law judge and the Administrator, al-
locating twenty-five days to the former for a recommendation and sixty-five
days to the latter for a final decision.30 The tightness of this schedule placed
enormous pressure on the agency to develop techniques for streamlining
suspension and cancellation proceedings. One response was the attempt to
codify the principles the agency would use in evaluating evidence of
carcinogenicity.
Since the mid-1950s, a number of scientific and public health institutions
have joined the International Union Against Cancer in endorsing the use of
animal studies in evaluating chemical carcinogenicity. Expert committees,
convened by such bodies as the World Health Organization, the Food and
Agriculture Organization and the National Academy of Sciences, agreed on
many of the criteria for conducting and interpreting such studies.31 When the
issue of carcinogenicity was raised, first with respect to DDT and then with
respect to the other major organo-chlorine pesticides, EPA sought to extract
from the statements and position papers issued by these organizations a set
of principles that would simplify its regulatory burden. The results achieved
25 Id. at 1299.
26 Pub. L. No. 92-516, 7 U.S.C. § 136 et seq. (1972).
27 Pub. L. No. 92-516, 7 U.S.C. § 4(c) (2) (1972).
28This was defined to mean "any unreasonable risk to man or the environment,
taking into account the economic, social, and environmental costs and benefits of the
use of any pesticide." 7 U.S.C. § 136(bb) (1972).
29 See Karch, "Explicit Criteria and Principles for Identifying Carcinogens: A
Focus of Controversy at the Environmental Protection Agency," reprinted in National
Academy of Sciences HA Decision-Making in the Environmental Protection Agency
(Washington, D.C.: National Academy of Sciences, 1977) 119 at 130.
30 Id.
31 Id. at 161-71.
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national prominence during the aldrin/dieldrin suspension proceedings when
EPA included in its final brief nine "principles of carcinogenicity" that the
agency claimed would be "applied to individual substances to determine their
human cancer hazard." These are listed below:
a) A carcinogen is any agent which increases tumor induction in man
or animals.
b) Well-established criteria exist for distinguishing between benign and
malignant tumors; however, even the induction of benign tumors is
sufficient to characterize a chemical as a carcinogen.
c) The majority of human cancers are caused by avoidable exposure to
carcinogens.
d) While chemicals can be carcinogenic agents, only a small percentage
actually are.
e) Carcinogenesis is characterized by its irreversibility and long latency
period following the initial exposure to the carcinogenic agent.
f) There is great variation in individual susceptibility to carcinogens.
g) The concept of a "threshold" exposure level for a carcinogenic
agent has no practical significance because there is no valid method
for establishing such a level.
h) A carcinogenic agent may be identified through analysis of tumor
induction results with laboratory animals exposed to the agent or
on a post hoe basis by properly conducted epidemiological studies.
i) Any substance which produces tumors in animals must be con-
sidered a carcinogenic hazard to man if the results were achieved
according to the established parameters of a valid carcinogenesis
test.
In the aldrin/dieldrin brief, these principles were accompanied by twenty-
seven pages of supporting material from published reports and testimony
taken by the agency. 33
Even on a casual reading of the nine principles, one is struck by their
hybrid character; with few exceptions, they combine significant elements of
both science and policy. The definition of a carcinogen in the first principle,
for example, rests on two assumptions that have more the character of policy
judgments than scientific findings: first, an agent that increases any type of
tumor production (even benign tumors) should be regarded as a carcinogen,
and second, carcinogenicity in laboratory animals should be accepted as an
indicator of potential human carcinogenicity. The latter assumption is spelled
out more explicitly in the ninth principle. Similarly, the seventh principle
assumes, largely as a matter of policy, that no threshold levels should be
established for carcinogens, because, as a matter of scientific fact, no valid
method exists for establishing such levels.
32 EPA, "Respondent's Brief, Proposed Findings and Conclusions on Suspension,"
(Sept. 16, 1974) at 28-57.
3 3 Karch, supra note 29, at 134.
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As the chemical industry and others began to react to the cancer
principles, EPA discovered that public approval would be far from easy to
secure. Chemical manufacturers questioned the scientific validity of EPA's
approach, correctly perceiving that the principles could become extremely
powerful tools in the hands of the regulatory agencies if they were left un-
challenged. Unwilling to jeopardize the aldrin/dieldrin suspension by en-
gaging in what promised to be a protracted controversy, EPA substantially
weakened its position on the cancer principles. For example, in his final
decision the EPA Administrator paraphrased the first principle in the follow-
ing way:
The once-significant distinction between tumors and cancers, or between tumori-
genic and carcinogenic substances, has lost much of its validity with the increasing
evidence that many tumors can develop into cancers. Thus, for purposes of
carcinogenicity testing, they should be considered synonymous. 34
In this more qualified version, the "principle" emerged as nothing more than
a policy conclusion backed up by considerable scientific authority. The
courts, as we have seen, were quite prepared to defer to the agency in a
matter "as sensitive and fright-laden as cancer. ' 35 EPA's watered-down
application of the principles aroused no judicial opposition.
In later regulatory proceedings involving heptachlor/chlordane (H/C)
and Mirex, EPA again relied on the cancer principles developed during the
aldrin/dieldrin case. The original list of nine was extended to seventeen and
revised several times, carefully incorporating suggestions made by Dr. Saf-
fiotti of the National Cancer Institute.36 In the H/C and the Mirex admini-
strative proceedings, EPA moved to have the seventeen principles officially
noticed as facts,37 but each time without success. The agency eventually
fared better at the hands of the judiciary. The Court of Appeals for the
District of Columbia Circuit specifically approved EPA's use of the principles
in the H/C suspension proceeding, stating that: "EPA's specific enunciation
of its underlying analytic principles, derived from its experience in the area,
yields meaningful notice and dialogue, enhances the administrative process
and further reasoned decision-making." 38
Throughout these manoeuverings, controversy over the status of the
cancer principles continued undiminished until EPA abandoned the principles
in favour of new procedures for assessing the cancer risk presented by envi-
ronmental pollutants.39 These included general guidelines for evaluating the
evidence of carcinogenicity and were couched in far more cautious and
qualified language than the cancer principles. The following brief extract
from the guidelines illustrates this point:
34 39 Fed. Reg. 37267 (1974).
35EDF v. EPA, 510 F.2d 1292, 1298n, 13 and accompanying text (D.C. Cir.
1975).
36 Karch, supra note 29, at 146-49.
37 Id. at 152, 153.
38EDF v. EPA, 548 F.2d 998 at 1007 (D.C. Cir. 1976).
39 Health Risk and Economic Impact Assessments of Suspected Carcinogens, 41
Fed. Reg. 21402 (1976).
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The best evidence that an agent is a human carcinogen comes from epidemio-
logical studies in conjunction with confirmatory animal tests. Substantial evidence
is provided by animal tests that demonstrate the induction of malignant tumors
that are generally recognized as early stages of malignancies. Suggestive evidence
includes the induction of only those non life-shortening benign tumors which are
generally accepted as not progressing to malignancy, and indirect tests of tu-
morigenic activity.... 4o
The EPA Administrator was also careful to point out that carcinogenic risk
assessment involves a two-step process: "The first decision is whether a
particular substance constitutes a cancer risk. The second decision is what
regulatory action, if any, should be taken to reduce that risk."'41 This state-
ment implicitly left open the possibility that a given piece of evidence, for
example, induction of benign tumours, could be accorded different weight at
the first and second stages of decision-making.
Soon after issuing these guidelines, EPA ceased to play a pre-eminent
role in developing federal policy on carcinogens. With the passage of the
Toxic Substances Control Act, primary jurisdiction over this problem shifted
to the Interagency Regulatory Liaison Group (IRLG), a body composed of
representatives from the five federal agencies entrusted with major responsi-
bility for co-ordinating toxic substances regulation. Extremely active in the
regulatory reform movement of the Carter years, IRLG seems to have died
a quiet death with the advent of the Reagan Administration. In the current
climate of deregulation, IRLG's demise is unlikely to signal renewed activism
by its individual member agencies on the problem of regulating environ-
mental carcinogens.
It is apparent from this complicated history that EPA's attempt to
systematize the regulation of carcinogens was neither wholly successful nor
a complete failure. The agency probably scored its greatest successes in the
courts. Reviewing courts seem to have regarded the cancer principles es-
sentially as open policy statements explaining in advance how the agency
would weigh and evaluate conflicting evidence of carcinogenicity. Viewing
the principles in this light, the courts agreed that they furthered "reasoned
decision-making" by exposing the underlying analytical framework adopted
by the agency.42 On the other hand, EPA was notably unsuccessful in muster-
ing broad scientific support for the cancer principles. Though the agency
asserted that the aldrin/dieldrin principles represented the "most advanced
research findings" available, 43 their scientific status remained in considerable
doubt. Efforts to get the seventeen revised principles officially noticed in the
H/C and Mirex proceedings were lost in controversy. As the later guidelines
on assessing suspected carcinogens indicate, EPA was eventually forced to
substantially modify its position on such issues as the significance of benign
turnours.
This analysis suggests that the courts and the scientific community were
4041 Fed. Reg. 21404 (1976).
4141 Fed. Reg. 21403 (1976).
4241 Fed. Reg. 21404 (1976).
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applying very different standards in assessing the validity of the cancer
principles. From the standpoint of the federal judiciary, the principles
could be accepted as valid decision-making tools because they were openly
announced and supported by a respectable body of expert opinion. They
also seemed consistent with the agency's apparently pressing mandate to
protect public health against the unique hazards presented by carcinogens.
Scientists, in contrast, rejected any attempt to develop apparently fixed
"principles" on matters that were-and to a large extent still are-being
vigorously debated by experts on carcinogenesis. In their view, a search for
principles could not be meaningfully undertaken as long as the underlying
scientific issues remained so controversial. 44 A similar tension between scien-
tific and judicial-administrative appraisals of validity prevaded the develop-
ment of OSHA's cancer policy, to which we now turn.
IV. THE REGULATION OF OCCUPATIONAL CARCINOGENS
The Occupational Safety and Health Act (OSH Act) of 1970 estab-
lished within the Department of Labor a new implementing agency, OSHA, 45
for the purpose of carrying out the overall objectives of the law, that is: "to
assure so far as possible every working man and women in the Nation safe
and healthful working conditions."46 The agency soon became one of the
most controversial regulatory arms of the federal government. In its early
years, OSHA was widely ridiculed for adopting thousands of highly specific
safety standards dealing with relatively trivial hazards in the work-place.
Critics of OSHA pointed to federal standards governing the placement of
hooks in toilet stalls or the spacing of rungs on ladders and argued that the
agency was doing much more to burden employers than to protect the safety
and health of employees. 47
The need to reform OSHA's image was recognized as a top priority by
the Carter Administration. As early as 1977, Eula Bingham, then Assistant
Secretary of Labor for Occupational Safety and Health, announced in a
policy statement that the agency would "shift to common sense priorities. '48
Outdated regulations would be eliminated, necessary regulations would be
revised and simplified, and renewed emphasis would be placed on the control
of serious hazards. Above all, the agency would assign more importance to
health issues than to safety. OSHA's celebrated "cancer policy", issued as a
final rule in January, 1980,4 9 offered tangible evidence of the agency's
determination to reorient its priorities and to set its house in order.
44 Id.
45 Pub. L. No. 91-596, §§ 29 and 30 provided for the appointment of an Assistant
Secretary of Labor for Occupational Safety and Health and the creation of twenty-five
additional positions in the Department of Labor to implement the Act.
4 6 Pub. L. No. 91-596, § 2(b)(1954), 29 U.S.C. § 651, (b)(3)(1970).
4 7 See, e.g., Smith, The Occupational Safety and Health Act (Washington D.C.:
American Enterprise Institute, 1976) at 74-77; Shaffer, "Job Health and Safety." Edito-
rial Research Repts. (Washington, D.C.: Congressional Quarterly, Inc., 1976) 953 at
965-66.
48 OSHA, The Shift to Common Sense Priorities (Washington, D.C.: O.S.H.A.,
1977).
49 45 Fed. Reg. 5001-5296 (1980).
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In the first six years of existence, OSHA exercised its rule-making
authority in developing standards for a number of individual carcinogens
(asbestos, vinyl chloride, arsenic, coke oven emissions, acrylonitrile) and
a group of fourteen organic compounds.60 Several factors intervened in 1976-
77 to bring about a radical departure from this pattern of substance-by-
substance regulation. With the enactment of the Toxic Substances Control
Act in 1976, public awareness of the long-term health hazards presented by
chemicals was at an all-time high, and OSHA was under considerable pres-
sure from its constituents, the labour unions, to speed up its own regulation
of toxic substances in the workplace. Chance personnel changes occurring
at this time also influenced the agency's course. A senior EPA staff member
moved to OSHA, bringing with him the experience gathered at EPA through
work on the cancer principles.51 In all, these circumstances favoured a new
approach to the regulation of chemical carcinogens.
A. Objectives of the Cancer Policy
By adopting generic rules for the identification, classification and regu-
lation of occupational carcinogens OSHA hoped, in the first instance, to
avoid the repetitions that had characterized both its own earlier regulation
of carcinogens and EPA's similar initiatives with respect to the organo-
chlorine pesticides. The cancer policy was designed to resolve once and for all
the repeatedly debated and litigated issues that seemed to surface in regu-
latory proceedings involving carcinogens: the validity of using animal studies
as a basis for regulation, methodological principles for conducting such
tests, and the proper role of epidemiological evidence. OSHA proposed to
argue these and related issues fully and openly in one elaborate rule-making
process. Its objective was to issue regulations based on these arguments and
its own educated policy judgment on matters in dispute. Once the generic
rules were in place, OHSA believed it could simplify the regulation of
individual substances because many troublesome issues would no longer
have to be reopened.
OSHA also hoped that the development of a generic policy would
assure consistency over time in the agency's treatment of occupational car-
cinogens. OSHA's top administration had undergone notoriously frequent
changes during the agency's first five years; Assistant Secretaries before
Bingham had generally held their positions for no more than eighteen
months. Staff members at OSHA believed that a regulation such as the can-
cer policy was needed to give the agency a stable sense of mission. Their
views were expressed in the introduction to the proposed carcinogens regu-
lations issued in October, 1977:
One obvious result of OSHA's current case-by-case approach to the regulation of
carcinogens has been the relitigation of certain key issues in each and every
rule-making. This taxes witnesses who have in the past been willing to testify in
prior rule-makings. In addition, the system hardly guarantees a continuity of
approach in every case, whether it be within the Agency or within the Courts.r 2
50 For an account of OSHA's early regulatory action on carcinogens, see Ashford,
Crisis in the Workplace, (Cambridge, Mass.: MIT Press, 1976) at 154-59.
51 Anson Keller became Special Assistant for Regulatory Affairs at OSHA.
5242 Fed. Reg. 54154 (1977).
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The cancer policy was designed not only to identify potential carcinogens,
but also to classify them according to the degree of risk they presented to
worker health. By this technique, OSHA expected to establish a rational
system of priorities for regulating the thousands of chemicals, many of them
suspected carcinogens, present in the American workplace. For all substances
assigned to the highest risk category, OSHA proposed to set control stan-
dards at the lowest "feasible" level, as authorized by the Occupational
Safety and Health Act.53 Section 655(b) (5) 5 of the Act provides that for
toxic materials or harmful physical agents the appropriate standard is the one:
[Which most adequately assures, to the extent feasible, on the basis of the best
available evidence, that no employee will suffer material impairment of health or
functional capacity even if such employee has regular exposure to the hazard
dealt with by such standard for the period of his working life.
By tying the proposed classification scheme to different levels of control,
OSHA blurred the line between decisions as to whether a substance presents
a cancer risk and decisions as to what regulatory action should be taken.
This was a distinction which EPA, as noted above,55 had been careful to
introduce in its own guidelines on carcinogenic risk assessment. OSHA's
departure from the EPA precedent was consistent with its desire to speed up
the regulation of occupational carcinogens, but in retrospect there is little
doubt that this decision increased the cancer policy's vulnerability to
political challenge.
B. Values in Conflict: Good Administration vs. Good Science
Issued as a final rule in January 1980, OSHA's cancer policy covered
almost 300 pages in the Federal Register, of which more than half were
devoted to the agency's analysis of specific scientific issues. The publication
capped more than three years of regulatory development, distilling the views
of at least fifty-four experts in the field of carcinogenesis and summarizing
a total record of over 250,000 pagesr'" At least on the surface, there could
be no question that OSHA had fully complied with the dictates of good
administrative practice. The agency had listened to experts from government,
industry and independent institutions. The decision-making record carefully
described their conflicting viewpoints and justified the agency's decision to
accept one or another position. Nevertheless, the publication of the cancer
policy drew an instant, hostile reaction from the chemical industry, whose
representatives immediately filed suit against OSHA. The reasons 'for this
outcome are examined in detail below.
1. Maximum Tolerated Dose: A False Impression of Consensus
At public hearings on the cancer policy held in May-July, 1978, OSHA
considered more than a dozen specific issues related to the conduct and
interpretation of carcinogenesis bio-assays. One of the more controversial
5342 Fed. Reg. 54185 (1977) (proposed rule); 45 Fed. Reg. 5286 (1980) (final
rule).
54 29 U.S.C. § 655(b)(5)(1970).
55 See text accompanying note 41, supra.
5645 Fed. Reg. 5008 (1980).
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was the propriety of testing at high doses. OSHA's handling of this issue
is analysed here in some depth, because it is symptomatic of the difficulties
encountered by the agency in resolving serious scientific disputes.
A key question posed by the agency to its expert witnesses concerned
the appropriateness of testing laboratory animals at the maximum tolerated
dose (MTD), usually defined as the highest dose administered during a
chronic study "that can be predicted not to alter the treated animals' normal
longevity from toxic effects other than carcinogenicity."' ' 7 Establishing the
MTD for any tested substance and any species of test animal involves a
prediction and experts may differ or simply err in making this judgment. In
spite of the possibility of varient opinions or outright error, however, many
of OSHA's witnesses approved the use of the MTD as one of the doses in
a cancer bio-assay. The opinion was frequently expressed that testing at the
highest tolerated dose offers the only practical alternative to tests using
unmanageably large numbers of animals at doses much closer to the levels
of expected human exposure. 58
Though the principle of testing at the MTD was widely supported on
practical grounds, several experts suggested that unavoidable biological effects
produced at such high doses could lead to distortions in the dose-response
curve. One theory that received considerable support, especially from industry
scientists,59 was that any chemical can induce cancer through "metabolic
overloading" of the body's natural detoxification mechanisms. A witness for
Dow Chemical summed up this hypothesis as follows: "Only relatively high
doses can, in practice, yield statistically significant data. But frequently such
high doses produce cancer simply because their very immensity overwhelms
the biochemical pathways that would detoxify smaller, more realistic doses." 600
Others suggested that the metabolic effects of high doses might interfere with
protective mechanisms, such as DNA repair, or cause the formation of
carcinogenic agents not formed at lower doses. The possibility of "secondary
carcinogenesis" at high doses, caused by tissue damage rather than direct
carcinogenic action (for example, through induction of bladder stones), was
also discussed by some scientists from the chemical industry."
OSHA cited a number of scientific reasons for not accepting these argu-
ments at face value. The agency noted, for example, that empirical evidence
in support of the "metabolic overloading" theory was generally limited.02
Bio-assay results on vinyl chloride actually seemed to contradict the hy-
pothesis that detoxification mechanisms were overwhelmed at high doses. The
agency also dismissed the evidence of "secondary carcinogenesis" as not
entirely convincing, noting that in most cases the alleged causal link between
57 Id. at 5084.
58 d. at 5085-5088.
59d. at 5088. OSHA's listing of some of the participants who supported this
theory reads like a who's who of the chemical industry.
60 1d. (emphasis added).
61 Id.
2 Id.
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tissue damage and cancer was either inconclusive or non-existent.6 OSHA
concluded, therefore, that it would continue to accept data from tests con-
ducted at high doses, although it expressed a willingness to evaluate any
"truly substantial scientific data" to support the "metabolic over-loading" or
"secondary carcinogenesis" hypotheses. 64
From the regulatory standpoint, the most noteworthy consequence of
this decision was that OSHA proposed three criteria that proponents of rival
mechanisms of carcinogenesis would have to meet before they could present
evidence in support of their theories. 5 The agency stipulated that arguments
about special mechanisms of carcinogenesis at high doses would only be
heard if accompanied by evidence showing that:
a) The tested substance produced metabolic products at high doses that
are not present at lower doses;
b) The metabolites produced at high doses were ultimate carcinogens
while those produced at lower doses were not;
c) The metabolites produced at high doses in animals were not pro-
duced in humans at lower doses.
Industry representatives interpreted this provision as an attempt by
OSHA to take back with one hand what it seemed to have granted with the
other, for they correctly perceived that the criteria would be impossible
to meet in the current state of scientific knowledge. 6 Although OSHA
admitted that evidence of metabolic disorders at high doses could be relevant
to a determination of carcinogenesis, the stringency of the criteria essentially
ruled out any possibility of introducing the "metabolic overloading" hypothe-
sis. In sum, the agency appeared to be arbitrarily foreclosing from further
consideration an area of potentially important scientific development. This
was a result that most scientists, whatever their political affiliations, would
not easily be prepared to accept.
The approach taken by OSHA to the MTD question also illustrates the
agency's relative insensitivity to the political character of the controversy
before it. The criteria for admitting evidence of metabolic overloading were
unilaterally developed by the agency without seeking an accommodation with
the parties most likely to disagree. Instead of functioning as a mediator
between conflicting expert viewpoints, OSHA, by this action, positioned itself
as a clear adversary to industry interests. Spokesmen for the Chemical
industry could claim with some justice that the criteria were more a legal
stratagem to curtail their rights than a reasoned response to disputed
scientific issues.
It is important to recognize, however, that OSHA had strong reasons
for its relative inflexibility in this matter. On strictly scientific grounds, the
63 Id.
04 ld. at 5093.
05 Id. at 5094.
06 Personal interview with Ronald Lang, Executive Director at American Industrial
Health Council, Scarsdale, N.Y. (June 25, 1981).
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agency found the secondary carcinogenesis theories unimpressive. Moreover,
OSHA had reason to expect that, given any opportunity to do so, industry
would continue to challenge the validity of high dosage testing, even on the
basis of weak empirical evidence. In light of the federal judiciary's record
of deference to the administrative agencies, OSHA could perhaps have
counted on upholding its position at the end of the day in court. But the
need to litigate these issues at all would bring back to the regulatory process
precisely the kinds of delay that the generic policy was designed to prevent.
Under the circumstances, the establishment of strict threshold criteria for the
introduction of certain types of evidence made very good administrative sense.
2. Negative Epidemiological Studies
The classification of carcinogens under the cancer policy depends on an
assessment of the relative risks presented by large numbers of candidate
substances. This, in turn, requires the evaluation of different types of evi-
dence, both positive and negative, from a variety of sources: human
epidemiological studies, long-term bio-assays involving laboratory animals
and supportive evidence from other sources, such as short-term mutagenicity
studies. From its prior regulatory experience, OSHA was well aware of a
strong possibility of conflicts among results obtained from different types of
studies. Such contradictions, the agency recognized, would have to be
consistently resolved to make possible a reasoned classification of carcino-
gens by degree of risk.
The evaluation of epidemiological studies in relation to animal tests
posed a specially critical problem for OSHA in this connection, particularly
since negative evidence from the studies was frequently in conflict with
positive results from the tests. Again, the agency adopted what appeared to
be a flexible position. In general, positive results from either human or
mammalian animal studies would supersede negative epidemiological evi-
dence, but the latter would still be considered if it conformed to certain
criteria.67 The difficulty with this approach lay, as before, in the nature of
the criteria developed by OSHA for passing on the adequacy of "non-
positive" human epidemiological studies.
In its final form, the cancer policy provided that non-positive human epi-
demiological studies would have to meet the following minimum criteria to
merit consideration by the agency:
a) The study should involve a group of subjects exposed to the sub-
stance for at least 20 years; the group should have been observed
for at least 30 years following exposure.
b) Documented reasons should be provided for predicting the sites at
which the substance would be expected to induce cancer.
c) The group of subjects should be large enough to permit detection
of an increase in cancer incidence of 50% above that in unexposed
controls. 68
6745 Fed. Reg. 5059 (1980).
68 Id. at 5059-5060.
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It requires no more than a passing familiarity with the current state of
epidemiology to recognize that these conditions would be practically im-
possible to satisfy in practice. At the same time, these criteria as well reflect
legitimate concerns about the quality of scientific evidence routinely sub-
mitted to the regulatory agencies by industry. Epidemiological studies, in
particular, are frequently flawed; among their most common shortcomings
are the inadequate size of the exposed group and the inconclusive length of
the observation period. One could argue from the agency's point of view,
therefore, that the criteria represented a valid device for screening out such
methodologically faulty surveys from the outset. 9 By excluding inadequate
and incomplete epidemiological data, OSHA could save valuable resources
that would otherwise be spent in evaluating and rebutting inconclusive
evidence.
The technique of using impossibly stringent criteria as an exclusionary
tool nonetheless raises troublesome questions from both an administrative
and a scientific viewpoint. OSHA's evidentiary criteria were designed only
for epidemiological studies indicating no positive correlation between ex-
posure and increased incidence of cancer. No parallel methodological con-
straints were proposed for studies tending to show positive evidence of
cancer risk. The criteria thus reflected an agency policy not only to accord
greater weight to positive than to non-positive studies, but also to apply a
lower standard of quality in evaluting the former than the latter.
Such an approach is perhaps legally defensible as being in accord with
the Occupational Safety and Health Act's highly protective mandate con-
cerning worker health. But clothing a basic policy judgment in the guise of
seemingly objective evidentiary "criteria" is more difficult to justify by the
standards of fair administrative practice. The use of such a technique sug-
gests that the agency is hiding a politically vulnerable decision behind a
facade of scientific rationality. This is a far cry from Davis' vision of an
agency structuring its discretion through open rule-making.
There is another, deeper problem with OSHA's effort to exclude
certain types of evidence by means of criteria for quality control. Few
decisions in the field of carcinogenic risk assessment rest on certain know-
ledge. The mechanisms of carcinogenesis, the methodology and interpretation
of animal and epidemiological studies, and the development of quantitative
risk assessments are all matters on which experts may differ. Sifting through
conflicting and uncertain evidence on such issues presents regulatory agencies
with problems not encountered in more ordinary factual inquiries. As the
District of Columbia Court of Appeals noted in reviewing one of EPA's
early regulatory decisions:
Looking to the future, and commanded by Congress to make policy, a rule-
making agency necessarily deals less with "evidentiary" disputes than with
normative conflicts, projections from imperfect data, experiments and simulations,
69 It should be noted as well that the proper methodology for conducting epi-
demiological studies is still a matter of debate in national and international scientific
circles. OSHA therefore could not fall back upon any ready-made scientific consensus
in designing its minimum criteria for non-positive studies.
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educated predictions, differing assessments of possible risks, and the like. The
process is quasi-legislative in character, and one will search it in vain for those
intermediate "findings" of fact which mark the midway point in an adjudicator's
linear march from raw evidence to single ultimate conclusion. 70
If this is an accurate description of modem regulatory decision-making,
then the legitimacy of the result depends in large part on how carefully the
agency considers and balances the probabilities before it. Indeed, the more
predictive and subjective the process becomes, the greater is the agency's
obligation to consider all factors relevent to a decision, regardless of the
direction in which they tend. In such a calculation, both the quantity and
quality of evidence may become crucial, for one moderately persuasive
positive study may be offset by several negative ones, each less conclusive
but cumulatively compelling. A fair assessment of the data would require
consideration of the complete dossier, making due allowance for the short-
comings of each individual study. Summary exclusion of certain types of
evidence from this delicate evaluation process, though supportable on
grounds of administrative convenience, could lead to distorted results that
no technical expert would find tenable.
3. The "Freezing of Science" Issue
The two examples discussed thus far reveal the extent of the conflict
between the purposes of the rule-making agency and the requirements of
sound scientific practice, as well as the tendency for technical disputes to
take on political overtones in regulatory proceedings. The conflict between
administrative efficiency and scientific credibility was openly discussed during
the cancer policy proceedings under the heading "freezing of science." The
central problem can best be stated in the agency's own language. Noting that
the purpose of the cancer policy was to improve the efficiency of rule-making,
ensure uniformity, and avoid relitigation of key issues, OSHA observed that:
"[I]t is necessary to strike a balance between some limitation of scientific
discussion, which is necessary to avoid regulatory paralysis, and the flexi-
bility to consider exceptional cases and to accommodate new scientific
advances." 7'
In its proposed regulations of 1977, OSHA attempted to strike this
balance through a system of rebuttable presumptions and a mechanism for
amending the generic regulations on the basis of new scientific evidence.
These devices, however, were criticized by pro-labour interests for permitting
a too easy reopening of supposedly foreclosed issues and by the chemical
industry for not providing sufficient opportunity to incorporate scientific
advances.
The final regulations promulgated by OSHA make significant conces-
sions to the position adopted by the chemical industry. Two major pro-
cedures were provided for ensuring that the cancer policy would remain
abreast of recent developments and incorporate the "best available evidence"
as required by section 655(b) (5) of the Act. First, the regulations would
70 Amoco Oil Co. v. EPA, 501 F.2d 722 at 735 (D.C. Cir. 1974).
7" 45 Fed. Reg. 5212.
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be subject to periodic review, at least once every three years, by the National
Cancer Institute (NCI), the National Institute for Environmental Health
Sciences (NIEHS) and the National Institute for Occupational Safety and
Health (NIOSH). 72 OSHA was required to consider proposed amendments
to the policy under four circumstances:
(1) A recommendation for amendment made individually or collectively by each
of the Directors of NCI, NIEHS and NIOSH after a required periodic review;
(2) a recommendation for amendment made individually or collectively by each
of the Directors of these Institutes, on their own motion; (3) a petition submitted
by the public which demonstrates new evidence or issues; and (4) the Secretary's
own motion.73
In addition, the regulations permitted amendments to the cancer policy
during standard-setting proceedings on individual carcinogenic substances.
Such amendments were to be based on "substantial new evidence" or "sub-
stantial new issues" related to the substance under regulatory consideration. 74
The provision for amending the generic regulations during particular
rule-making proceedings, not included in the 1977 proposal, represented a
positive response to the chemical industry's demand for "flexibility". In the
final rule, the right to initiate an amendment proceeding during an individual
standard-setting process was constrained principally by the requirement that
issues or evidence in support of such a petition be "substantial". If not
strictly construed, this provision could simply serve as an open door to every
available scientific counter-argument, thus undermining OSHA's fundamental
objective of insulating key issues from continual debate.
This extended discussion of the OSHA cancer policy has highlighted
some of the principal dilemmas that now confront American regulators in
their evalution of complex scientific and technical issues. Values cherished by
American administrative agencies-uniformity, continuity, certainty-seem
frequently at odds with the demands of science, particularly in areas of
rapidly developing knowledge. Entrusted with increasingly complicated tasks,
and working under stringent timetables and the ever present threat of
litigation, agencies like OSHA and EPA find more and more attractive the
possibility of simplifying the issues in dispute and, if possible, permanently
foreclosing debate on some of them. But as the examples of high-dosage
testing and negative epidemiological studies show, agencies may have to
engage in arbitrary exercises of discretionary power in carrying out such
simplification. In particular, a decision to systematically exclude certain
categories of evidence may be impossible to justify either on scientific
grounds or from the standpoint of fair and rational decision-making.
Equally important, the procedural safeguards accompanying rule-making
in the United States do not provide the means for striking a genuine com-
promise between conflicting scientific viewpoints. American courts and
administrative agencies have long subscribed to the idea that rule-making
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permits complex scientific questions to be "resolved in the crucible of debate
through the clash of informed but opposing scientific and technological
viewpoints."75 The proliferation of hybrid rule-making procedures and the
development of the "hard look" doctrine of review70 both reflect the assump-
tion that scientific controversies can be resolved through a full airing of the
disputed issues. The record of OSHA's cancer policy rule-making suggests,
however, that procedures alone cannot resolve conflicts in which scientific
issues are linked to deeper economic and political interests. Indeed, a stable
consensus in such cases may sooner be achieved in an atmosphere of
mediation and conciliation than in the crucible of public debate. But if rule-
making under appropriate procedures does not provide a satisfactory answer
to the problems of technically complex decision-making, are there any
reasonable alternatives? This question is addressed below by way of a brief
comparative analysis of European approaches to the regulation of occu-
pational carcinogens.
V. INTERNATIONAL COMPARISONS
The problem of protecting workers against occupational exposure to
carcinogens is, of course, endemic to all industrial societies, particularly
those with a developed capacity for chemical production. The methods used
in West Germany and Britain to deal with this problem are briefly con-
sidered here in order to determine whether significantly different regulatory
systems can better resolve the tensions between science, politics and admini-
strative practices experienced by OSHA.
West Germany's legal and institutional structure for regulating carcino-
gens in the workplace limits administrative discretion in ways that minimize
the need for procedural rigour. To begin with, the governing law 77 authorizes
public officials to take action against occupational hazards related to toxic
substances, but does not place upon any administrative agency an affirmative
obligation to develop protective health and safety standards for such agents. 78
The German regulatory process also bypasses the need for government to
referee scientific disagreements by delegating the responsibility for resolving
75 Int'l Harvester Co. v. Ruckelshaus, 478 F.2d 615 at 652 (D.C. Cir. 1973) (con-
curring opinion of Chief Judge Bazelon).
71 This doctrine, perhaps most ably propounded by the late Judge Harold Leventhal
of the U.S. Court of Appeals for the D.C. Circuit, requires reviewing courts to ensure
that agencies have taken a "hard look" at the problems before them. See e.g., Leven-
thal, Environmental Decisionmaking and the Role of the Courts (1974), 122 U. Pa. L.
Rev. 509 at 511-12.
77 Act on Protection against Dangerous Substances (Gesetz Zum Schutz vor gejiihr-
lichen Stossen), vom 16 Sept. 1980 (BG-BLI I.S. 1718). Short title: Chemicals Act
(Chemikaliengesetz).
78 Section 19 of the Chemicals Act provides generally that the federal government
may regulate hazardous substances in the workplace "insofar as it is necessary to protect
human life or health including worker protection and humane job planning." Beyond
this, the provision lists a variety of specific control measures that may be prescribed
by federal regulation, such as controls on the condition and layout of the workplace,
packaging and labeling requirements and ambient standards.
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such conflicts to experts committees representing labour, management, gov-
ernment and academic scientists.
Two technical advisory bodies play a dominant role in setting Germany's
occupational safety and health standards for chemicals. The first, an in-
dependent group formed under the auspices of the Deutsche Forschungsge-
meinschaft (DFG), 79 determines safe levels of exposure for most toxic
substances in the workplace. Maximum exposure standards 0 established by
the DFG committee are officially published by the Ministry of Labour, thus
achieving the character of binding standards for industry. This committee
also prepares a separate, annually updated list of carcinogens found in the
German workplace.81 For these substances, the committee does not undertake
to establish standards, endorsing the widely-held view that there is no valid
method for determining safe exposure levels for carcinogens. To develop
enforceable standards for these substances, the labour ministry makes use of
a supplementary rule-making process supervised by a second pluralistic
advisory committee. Following the designation of a substance as a carcino-
gen, the ministry's own advisory committee on toxic substancess2 assigns to
it a so-called "technically directed standard", s 3 taking into consideration
economic and technical factors, as well as information about risk.
Both expert committees involved in the process of setting standards
for occupational carcinogens represent divergent political interests. The DFG
committee consists of scientists from industry and academic research institu-
tions; the committee formed by the Ministry of Labour is even more
elaborately representative, drawing its members from labour unions and the
medical establishment, as well as from industry. The pluralistic structure of
these committees serves an important political purpose, permitting scientists
affiliated with different political interests to iron out their technical and policy
differences without having to expose their disputes to public view. Since
membership remains fairly stable over time, the committees provide a
relatively consistent approach to regulatory problems. Above all, the com-
mittee system makes it possible to avoid the tensions between administrative
and scientific principles that surfaced during OSHA's effort to develop the
generic cancer policy. Composed primarily of scientists and operating without
specific statutory authorization, the committees are protected against both
legal and political pressure to act according to prescribed procedures, or to pro-
duce regulatory results within a mandatory timetable. Since decision-making
is governed by scientific rather than administrative criteria, chemicals tend
79 The group is officially known as the Senate Commission on the Testing of
Workplace Substances Posing a Danger to Health (Senatskommission zur Priifung
gesundheitsschlidlicher Arbeitsstoffe).
IsoThe standards are known as "maximum workplace concentrations" (Maximale
Arbeitsplatzkonzentrationen, MAK-Werte).
81A revised list of carcinogens is published each year along with the annually
updated list of MAK-Werte.
82 Committee for Dangerous Substances in the Workplace (Ausschuss fiUr gefdhr-
liche Arbeitsstoffe, AGA).
83 Technische Richtkonzentrationen, TRK-Werte.
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to be regulated on a case-by-case basis, with new findings accommodated as
they become available. Such an incremental process generates no demand for
generic policy-making or for the closure of debate on controversial scientific
issues in the interests of administrative efficiency.
The British regulatory system for toxic hazards in the work place
resembles the German system in several important features, though there
are significant differences of philosophy between regulators in the two
countries. The Health and Safety at Work etc. Act84 of 1974, which controls
all danger to worker health from toxic substances, states the obligations of
government officials even less explicitly than the corresponding German law.
The basic duty to design and implement control measures against carcinogens
or other chemicals is assigned to manufacturers and users of such sub-
stances.85 Government plays a facilitating role in the policy process, deve-
loping regulations where necessary, but generally relying on negotiated
standards and voluntary codes of practice to achieve health and safety
objectives. Nothing in the British law forces a departure from case-by-case
evaluation of chemical hazards; an approach that avoids direct conflict
between scientific flexibility and administrative efficiency.
As in the German case, the British regulatory framework has little
need of formal procedural rules to promote consensus. Under the Health
and Safety at Work etc. Act the concept of representative decision-making
has been institutionalized through the creation of several "tripartite" bodies,
such as the Health and Safety Commission and the Advisory Committee on
Toxic Substances (ACTS), composed of representatives from labour, manage-
ment and government. ACTS (with the assistance of technical subcommittees
as needed) is primarily responsible for hearing and resolving disputes related
to specific hazardous substances. Like the comparable German expert com-
mittees, it operates out of the public eye and without recourse to formal
administrative procedures. Its members can resolve their differences of
opinion, whether motivated by scientific or political considerations, through
direct negotiation and compromise.
In comparison with the United States, both Germany and Britain have
displayed a remarkable facility for circumventing potential conflicts among
the scientific, administrative and political considerations involved in regu-
lating occupational carcinogens. Despite their fundamentally different legal
and political traditions, the two European countries have employed the same
basic techniques to avoid the regulatory dilemmas confronted by OSHA in
the United States. In the first place, the ocupational safety and health laws
84 Health and Safety at Work etc. Act, 1974, c. 37 (U.K.).
85 Section 6 of the Health and Safety at Work etc. Act, 1974, c. 37 (U.K.) imposes a
general duty on "any person who designs, manufacturers, imports or supplies any article
for use at work -
(a) to ensure, so far as is reasonably practicable, that the article is so de-
signed and constructed as to be safe and without risks to health when
properly used."
The provision also requires manufacturers to test products to the extent necessary for
compliance with the general duty clause and to provide information to users.
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of Germany and Britain sketch out a more modest regulatory agenda with
respect to chemicals than the American Occupational Safety & Health Act.
Neither explicitly nor implicity are administrative agencies in either country
required to undertake systematic control of all toxic substances to which
workers are exposed. Regulation of such hazards can therefore proceed
through case-by-case review of individual chemicals suspected of damaging
worker health. The idea of a generic policy for identifying, classifying and
regulating all carcinogens has attracted little support in this context.
Further, the legal and institutional systems of both Germany and Britain
minimize the need for government to establish and explain its regulatory
priorities through rule-making. British legislation, for example, assigns the
duty to guard against cancer risks principally to those who create and, to a
lesser extent, those who are exposed to such risks: manufacturers, employers
and employees.86 The general duty clauses of the Health and Safety at Work
etc. Act require, in effect, that these private parties, rather than the competent
public regulatory authority, should assume responsibility for identifying and
controlling potential carcinogenic hazards in the workplace.87 Though Ger-
man law does not expressly endorse the concept of self-regulation, the task of
establishing regulatory priorities in that country is tacitly assumed by a
non-governmental body, the DFG expert committee, which identifies targets
of regulation for the labour ministry through its annually published list of
occupational carcinogens.
Finally, the representative expert committees of both European countries
provide an effective forum for resolving political as well as scientific con-
troversies. Implicitly recognizing the linkage between science and politics
in the regulatory environment, both Germany and Britain have created in-
stitutions capable of mediating technical differences among experts holding
different political allegiances. Constrained neither by procedural rules nor
publication requirements, these committees can achieve consensus on dis-
puted issues with greater ease than is ordinarily possible in the open and
adversarial setting of administrative rule-making in the United States.
VI. CONCLUSION
This brief detour through two European regulatory systems throws into
relief the special complexity of the American administrative process and
underscores the difficulty of proposing for the United States any simple
guidelines for regulatory reform. The structure of the American regulatory
system requires, in effect, that administrative decision-making in areas of
scientific complexity, such as the control of occupational carcinogens, must
meet a three-way standard of legitimacy: the administrative, the scientific
86 Health and Safety at Work etc. Act, 1974, c. 37 ss. 2-7 (U.K.).
87 In placing greater emphasis on private regulatory behaviour, the Health and
Safety at Work etc. Act, 1974, c. 37 (U.K.) simply followed the recommendation of
the influential Robens Committee, which proposed in its 1972 report that a new occu-
pational safety and health law should encourage more "personal responsibility and
voluntary, self-generating effort." See Robens, Safety and Health at Work - Report of
the Committee 1970-72 (London: Her Majesty's Stationary Office, 1972) 7.
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and, ultimately, the political. Confronted with broad or vaguely worded
statutory mandates, administrators are expected to structure their discretion
through rule-making in accordance with the dictates of good administrative
practice. At the same time, their decisions are required by law to incorporate
the best available scientific evidence and, as a practical matter, to satisfy
the political demands of affected interfs-t groups. The problems encountered
by OSHA in promulgating its generic cancer policy illustrate in a particularly
acute form the tensions and contradictions among these conflicting require-
ments.
For administrative officials in Britain and West Germany, the task of
regulating risks to worker health presents itself from the outset in a much
more simplified form. In contrast to the Occupational Safety & Health Act,
the applicable laws of both European countries are noticeably reluctant to
spell out in explicit terms the nature and scope of governmental responsi-
bility in the field of worker protection. Although they confer substantial
regulatory powers on administrators, the European statutes are generally
silent as to the circumstances in which this authority should be invoked and
the substantive and procedural limits within which it should be exercised. 88
Accordingly, regulators in both European countries enjoy a large measure
of discretion which they, unlike their American counterparts, are not re-
quired to narrow through the techniques of administrative rule-making.
Relieved of the pressure to comply with procedural requirements,
administrators in Britain and West Germany need only meet the dual
standards of scientific and political acceptability in fulfilling their regulatory
objectives. Their success is ensured to a considerable extent through the
creation of representative expert groups which permit scientific and political
disputes to be resolved within a single institutional forum. By restricting
membership on these committees to acknowledged scientific experts, the
regulatory process guarantees, at a minimum, that decisions will conform
to established norms of scientific validity. At the same time, interest group
representation on these key decision-making bodies promotes the formation
of a stable consensus on genuinely controversial issues.
The lessons that American regulatory reformers can draw from these
European examples are necessarily limited by the unique legal and political
context of administrative decision-making in the United States. In particular,
the two most important preconditions for continued elaborate rule-making
-delegation of unstructured discretion and political demands for its sub-
sequent curtailment-seem to occupy a permanent place in the American
legislative and administrative process. It thus appears inevitable that Ameri-
can administrators, more than their European counterparts, must keep
contending with the triple claims of science, politics and administrative
procedure in their effort to develop new regulations. But the case of OSHA's
cancer policy suggests that a simple application of Davis' formula for rule-
8SBy contrast, American 6nvironmental and public health legislation in recent
years has frequently fallen back on complex procedural requirements as a device for
constraining agency discretion. See Scalia, Vermont Yankee: The APA, the D.C. Circuit
and the Supreme Court, (1978), Sup. Ct. Rev. 345 at 386-88.
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making cannot adequately handle the problems created by scientific complexity
and uncertainty during this process. OSHA's attempt to codify the scientific
issues under consideration and to foreclose debate not only failed to silence
controversy, but resulted, ironically, in arbitrary rule-making that violated
even the standards of legitimate administrative practice.
What, then, are the choices that realistically face an agency like OSHA
in the future? One course that runs counter to the Davis prescription is
to eschew rule-making except where it is absolutely necessary and to adopt
a pragmatic, case-by-case approach to most regulatory decisions. This is the
route that FDA selected in implementing the Delaney Clause with, as in-
dicated above, considerable political success. It is also the preferred avenue
for regulators dealing with occupational safety and health problems in
Germany and Britain. EPA's cancer principles suggest an alternative course
that satisfies some of the functions of generic rule-making, but does not
"freeze" science to the extent contemplated in OSHA's original cancer
policy proposal. Basically, EPA's approach relies on clearly articulated
decision-making principles, rather than formal rules, to structure adminis-
trative discretion and to provide a rational basis for future decisions. This
technique appears particularly well-suited to the context of chemical control,
since it permits an open declaration of policy without necessitating too
great a loss of flexibility.
The combined experiences of FDA, EPA and OSHA in regulating
carcinogens suggest that in areas of pronounced scientific controversy, rule-
making may introduce an unacceptable rigidity into the administrative
process. 9 But a more flexible approach is unlikely, by itself, to produce
the kind of political accommodation that is needed to regulate effectively in
the face of great scientific uncertainty. At least two European governments
have attempted to solve this dilemma through the use of "representative
expertise" and their policies merit closer study by American regulators.90 The
pressing task for federal administrators is to design for such groups an
effective role in resolving controversy, without sacrificing the openness and
public accountability that characterize the American regulatory process at
its best.
8An analysis of the OSHA cancer policy that reaches somewhat different con-
clusions about the value of generic rules may be found in McGarity, Substantive and
Precedural Discretion in Administrative Resolution of Science Policy Questions: Regu-
lating Carcinogens in EPA and OSHA (1979), 67 Georgetown L.J. 729.
90 It should be noted in this connection that the American Industrial Health
Council (AIHC), an influential chemical industry trade association, has proposed the
establishment of a scientific review panel with sole responsibility for identifying and
classifying occupational carcinogens. However, the proposal does not explicitly provide
for an equal representation of labour and management interests on the panel. OSHA's
reasons for rejecting AIHC's proposal in its original form are discussed at 45 Fed. Reg.
5203-5204 (1980).
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